You've read the longevity threads, listened to the podcasts, and NAD+ keeps surfacing as the metabolic thread that ties energy to aging. Before you start, there's a quieter question worth putting on the table: how does NAD+ sit alongside your blood sugar, and why might a good provider look there first?
Why NAD+ shows up in every longevity conversation
NAD+ (nicotinamide adenine dinucleotide) is a coenzyme present in every cell you have. Its job is unglamorous but central: it shuttles electrons through the reactions that turn food into usable energy, and it acts as a substrate for enzymes involved in DNA repair and cellular signaling [1]. When people talk about NAD+ and "energy," they are pointing at this real biochemistry — not a marketing metaphor.
Tissue NAD+ levels appear to decline with age in humans and animal models, which is why it has become a research target for metabolic and aging science [2]. That's the appeal for someone rebuilding after fragmented postpartum sleep, or someone whose time-zone recovery takes longer each year. It's also why the honest version of this conversation stops short of promises: declining levels are documented, but restoring energy and reversing aging are not settled outcomes. The science is active, not concluded.
The glucose connection most people skip
Here is the part that rarely makes the podcast summary. NAD+ metabolism and glucose metabolism run on the same wiring.
NAD+ is the currency of the cellular pathways — glycolysis, the citric acid cycle, oxidative phosphorylation — that process the sugar in your bloodstream [1]. It's also the fuel for sirtuins, a family of enzymes that influence how cells respond to insulin and manage fuel [3]. Because these systems overlap, researchers studying NAD+ precursors have specifically measured glucose handling and insulin sensitivity as outcomes of interest [4].
That's the reason a thoughtful provider may want a look at your glucose picture before you start anything. Not because NAD+ support is inherently a glucose intervention, but because energy, metabolism, and blood sugar are not separate rooms — they share a floor. If your fasting insulin is quietly drifting, that context matters for interpreting how you feel and what a plan should watch.
What a provider may actually look at
Beyond a symptom conversation, an independent provider building an energy-focused plan may review a small panel of metabolic markers. Common ones include:
- Fasting glucose. The American Diabetes Association defines normal fasting glucose as below 100 mg/dL, 100–125 mg/dL as prediabetes, and 126 mg/dL or higher (confirmed) as diabetes [5].
- Hemoglobin A1c. A three-month average of blood sugar; the ADA uses below 5.7% as normal, 5.7–6.4% as prediabetes, and 6.5% or above as diabetes [5].
- Fasting insulin. Not a diagnostic threshold on its own, but a window into how hard your body is working to keep glucose in range — useful context alongside glucose.
The point of a baseline isn't to find something wrong. It's to know where you actually sit before you change any inputs — so that later, when you report how you feel, there's something objective underneath the story. For someone who researches obsessively and is tired of "that's just this season," seeing your own numbers is the difference between a plan and a guess.
mg/dL · marker = Normal cutoff
The NAD+ options — and the honest caveats
People pursue NAD+ support along a few different routes: oral precursors like nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN), and injectable or IV forms of NAD+ itself. The evidence base varies considerably across these.
Human trials of NR have shown it can raise blood NAD+ levels and has generally been well tolerated in short studies [6]. That's a real, measurable pharmacologic effect — but "raises a biomarker" is not the same as "delivers the clinical benefit you're hoping for," and the trials are modest in size and length [6]. NMN research in humans is earlier still. It's worth reading the primary literature rather than the supplement copy.
A note on regulatory status, because it matters for anyone comparing options: the FDA has stated that NMN is excluded from the definition of a dietary supplement, a position that has shaped what's legally available and how [7]. And where a plan involves compounded medications: Compounded medications are not reviewed or approved by the FDA for safety, effectiveness, or quality. Compounded products are not equivalent to or interchangeable with any FDA-approved brand-name drug. Availability varies by state.
None of this is a reason to dismiss NAD+ support. It's a reason to enter it with clear eyes, a baseline, and a provider who monitors rather than assumes.
What the first few weeks realistically look like
If you and an independent provider decide to move forward, the early phase is about establishing a baseline and observing — not chasing a transformation.
- Baseline first. Labs and a symptom picture before any changes, so there's a real starting line.
- Early observation. How you feel, tolerability, and how your routine holds up against travel or broken sleep. Subjective, but tracked deliberately.
- Recheck and adjust. A follow-up conversation where your reported experience is read against your markers, and the plan is refined by the provider.
For the frequent flyer, the honest question isn't "will this fix jet lag" — it's "does this fit a calendar that changes weekly, with a team that adjusts around it." For someone nursing, the first question a provider should raise is whether any intervention is appropriate at all during breastfeeding; that's a clinical judgment, and a plan should ask it out loud rather than skip past it.
This article is educational and is not medical advice, diagnosis, or a recommendation to take any specific product or medication. Whether anything is appropriate for you — and whether it's ever prescribed — is a decision only an independent licensed provider can make.
Where Velri fits
Velri is a technology and coordination company — not a medical practice. What Velri does is remove the assembly work: coordinating lab orders so you can see your own baseline, connecting you with an independent, licensed provider group for an evaluation, and — only if that provider determines it's appropriate and writes a prescription — coordinating with an independent licensed pharmacy for fulfillment. A prescription is never guaranteed; it's the provider's decision, made from your markers and your history. For someone who wants a monitored, adjustable plan instead of another shelf of supplements, that's the role Velri plays: the logistics and the follow-through, with the clinical judgment left to the clinicians.
